{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T17:57:18Z","timestamp":1792173438151,"version":"4.4.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,6,29]],"date-time":"2021-06-29T00:00:00Z","timestamp":1624924800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,6,29]],"date-time":"2021-06-29T00:00:00Z","timestamp":1624924800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Allergy Asthma Clin Immunol"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Hereditary angioedema (HAE) is a rare but serious disorder associated with a multifaceted burden of illness including a high prevalence of psychiatric symptoms and impaired health-related quality of life (HRQoL). Despite recent efforts to clarify the psychosocial implications of HAE, important gaps still remain. The aim of this study was to characterize the psychosocial burden associated with HAE types 1 and 2.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Type 1 or 2 HAE patients (n \u2009=\u2009 17), aged 19\u00a0years or older, completed the Depression, Anxiety, Stress Scale (DASS-21) and the DSM-5 cross cutting measures to identify psychiatric symptomatology, Angioedema Quality of Life Questionnaire (AE-QoL) and the Short-Form 36-Item Health Survey version 2 (SF-36v2) to assess disease-related and generic HRQoL respectively, and the Work Productivity and Activity Impairment Questionnaire (WPAI) to measure impact on work productivity and daily activities. Data analyses were conducted using SPSS statistical software (Version 25.0; IBM, Armonk, NY). Descriptive statistics were used to summarize continuous demographics and clinical characteristics and outcomes of interest while frequency distributions were used for categorical variables. T tests were used to compare SF-36v2 domain scores to Canadian norms and sex differences in scale scores.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Depression [DASS-21 score \u2009=\u2009 6.8 \u2009\u00b1\u2009 10.2; n \u2009=\u2009 12 (71%)] anxiety [DASS-21 score \u2009=\u2009 6.2 \u2009\u00b1\u2009 8.2; n \u2009=\u2009 13 (76%)] and stress [DASS-21 score \u2009=\u2009 10 \u2009\u00b1\u2009 10.2; n \u2009=\u2009 13 (76%)] were prevalent. Other psychiatric symptoms warranting inquiry included mania (n \u2009=\u2009 14, 82.4%), anger (n \u2009=\u2009 14, 82.4%), sleep disturbances (n \u2009=\u2009 13, 76.5%), somatic symptoms (n \u2009=\u2009 11, 64.7%) and impaired personality functioning (n \u2009=\u2009 9, 52.9%). Mean AE-QoL score was 39 \u2009\u00b1\u2009 18.2. Mean SF-36v2 domain scores were significantly lower than Canadian normative data for the entire sample (p \u2009&lt;\u2009 0.05). Impairment in work productivity was minimal; mean activity impairment was 20.6% \u2009\u00b1\u2009 21.1% [n \u2009=\u2009 11 (64.7%)]. Female participants reported significantly greater HAE-related stress [DASS; t(15) \u2009=\u2009 \u00a0\u2212\u00a02.2, p \u2009=\u2009 0.04], greater HAE-related fears [AEQoL; t(5.6) \u2009= \u2009\u00a0\u2212\u00a02.7, p \u2009=\u2009 0.04), and lower SF-36v2 domain scores than male patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Study findings offer specific, valuable insight into the psychosocial burden of HAE with the potential to improve clinical management of HAE. Best practices for effective management of HAE should include providing holistic care to address the psychosocial and mental health of HAE patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13223-021-00563-0","type":"journal-article","created":{"date-parts":[[2021,6,29]],"date-time":"2021-06-29T09:02:46Z","timestamp":1624957366000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["Psychosocial burden of type 1 and 2 hereditary angioedema: a single-center Canadian cohort study"],"prefix":"10.1186","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4949-1459","authenticated-orcid":false,"given":"Julia","family":"Hews-Girard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marilyn Dawn","family":"Goodyear","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,6,29]]},"reference":[{"issue":"5","key":"563_CR1","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1016\/j.jaip.2013.07.002","volume":"1","author":"BL Zuraw","year":"2013","unstructured":"Zuraw BL, Banerji A, Bernstein JA, Busse PJ, Christiansen SC, Davis-Lorton M, et al. US Hereditary Angioedema Association Medical Advisory Board 2013 recommendations for the management of hereditary angioedema due to C1 inhibitor deficiency. J Allergy Clin Immunol Pract. 2013;1(5):458\u201367.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"8","key":"563_CR2","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1111\/all.13384","volume":"73","author":"M Maurer","year":"2018","unstructured":"Maurer M, Magerl M, Ansotegui I, Aygoren-Pursun E, Betschel S, Bork K, et al. The international WAO\/EAACI guideline for the management of hereditary angioedema-The 2017 revision and update. Allergy. 2018;73(8):1575\u201396.","journal-title":"Allergy"},{"issue":"2","key":"563_CR3","first-page":"151","volume":"14","author":"M Davis-Lorton","year":"2015","unstructured":"Davis-Lorton M. An update on the diagnosis and management of hereditary angioedema with abnormal C1 inhibitor. J Drugs Dermatol. 2015;14(2):151\u20137.","journal-title":"J Drugs Dermatol"},{"issue":"6","key":"563_CR4","doi-asserted-by":"publisher","first-page":"383","DOI":"10.18176\/jiaci.0102","volume":"26","author":"T Caballero","year":"2016","unstructured":"Caballero T, Maurer M, Longhurst HJ, Aberer W, Bouillet L, Fabien V, et al. Triggers and prodromal symptoms of angioedema attacks in patients with hereditary angioedema. J Investig Allergol Clin Immunol. 2016;26(6):383\u20136.","journal-title":"J Investig Allergol Clin Immunol"},{"issue":"1","key":"563_CR5","doi-asserted-by":"publisher","first-page":"47","DOI":"10.2500\/aap.2013.34.3685","volume":"35","author":"T Caballero","year":"2014","unstructured":"Caballero T, Ayg\u00f6ren-P\u00fcrs\u00fcn E, Bygum A, Beusterien K, Hautamaki E, Sisic Z, et al. The humanistic burden of hereditary angioedema: results from the burden of illness study in Europe. Allergy Asthma Proc. 2014;35(1):47\u201353.","journal-title":"Allergy Asthma Proc"},{"issue":"2","key":"563_CR6","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1007\/s12016-016-8575-2","volume":"51","author":"H Longhurst","year":"2016","unstructured":"Longhurst H, Bygum A. The Humanistic, societal, and pharmaco-economic burden of angioedema. Clin Rev Allergy Immunol. 2016;51(2):230\u20139.","journal-title":"Clin Rev Allergy Immunol"},{"issue":"5","key":"563_CR7","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.anai.2013.08.019","volume":"111","author":"A Banerji","year":"2013","unstructured":"Banerji A. The burden of illness in patients with hereditary angioedema. Ann Allergy Asthma Immunol. 2013;111(5):329\u201336.","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"6","key":"563_CR8","doi-asserted-by":"publisher","first-page":"706","DOI":"10.2340\/00015555-2014","volume":"95","author":"A Bygum","year":"2015","unstructured":"Bygum A, Ayg\u00f6ren-P\u00fcrs\u00fcn E, Beusterien K, Hautamaki E, Sisic Z, Wait S, et al. Burden of illness in hereditary angioedema: a conceptual model. Acta Derm Venereol. 2015;95(6):706\u201310.","journal-title":"Acta Derm Venereol"},{"issue":"Pt 2","key":"563_CR9","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1348\/014466505X29657","volume":"44","author":"JD Henry","year":"2005","unstructured":"Henry JD, Crawford JR. The short-form version of the Depression Anxiety Stress Scales (DASS-21): construct validity and normative data in a large non-clinical sample. Br J Clin Psychol. 2005;44(Pt 2):227\u201339.","journal-title":"Br J Clin Psychol"},{"key":"563_CR10","unstructured":"Association AP. DSM-5 self-rated level 1 cross-cutting symptom measure\u2014adult. 2013."},{"issue":"3","key":"563_CR11","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/j.jaip.2015.12.010","volume":"4","author":"N Prior","year":"2016","unstructured":"Prior N, Remor E, Perez-Fernandez E, Caminoa M, Gomez-Traseira C, Gaya F, et al. Psychometric field study of hereditary angioedema quality of life questionnaire for adults: HAE-QoL. J Allergy Clin Immunol Pract. 2016;4(3):464-73 e4.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"6","key":"563_CR12","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1097\/00005650-199206000-00002","volume":"30","author":"JE Ware Jr","year":"1992","unstructured":"Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992;30(6):473\u201383.","journal-title":"Med Care"},{"issue":"5","key":"563_CR13","doi-asserted-by":"publisher","first-page":"353","DOI":"10.2165\/00019053-199304050-00006","volume":"4","author":"MC Reilly","year":"1993","unstructured":"Reilly MC, Zbrozek AS, Dukes EM. The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics. 1993;4(5):353\u201365.","journal-title":"Pharmacoeconomics"},{"issue":"1","key":"563_CR14","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/1710-1492-6-17","volume":"6","author":"L Bouillet","year":"2010","unstructured":"Bouillet L. Hereditary angioedema in women. Allergy Asthma Clin Immunol. 2010;6(1):17.","journal-title":"Allergy Asthma Clin Immunol"},{"issue":"4","key":"563_CR15","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/j.anai.2013.05.028","volume":"112","author":"AS Fouche","year":"2014","unstructured":"Fouche AS, Saunders EF, Craig T. Depression and anxiety in patients with hereditary angioedema. Ann Allergy Asthma Immunol. 2014;112(4):371\u20135.","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"6","key":"563_CR16","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1016\/j.anai.2020.02.018","volume":"124","author":"A Banerji","year":"2020","unstructured":"Banerji A, Davis KH, Brown TM, Hollis K, Hunter SM, Long J, et al. Patient-reported burden of hereditary angioedema: findings from a patient survey in the United States. Ann Allergy Asthma Immunol. 2020;124(6):600\u20137.","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"5","key":"563_CR17","doi-asserted-by":"publisher","first-page":"407","DOI":"10.2500\/aap.2010.31.3394","volume":"31","author":"WR Lumry","year":"2010","unstructured":"Lumry WR, Castaldo AJ, Vernon MK, Blaustein MB, Wilson DA, Horn PT. The humanistic burden of hereditary angioedema: Impact on health-related quality of life, productivity, and depression. Allergy Asthma Proc. 2010;31(5):407\u201314.","journal-title":"Allergy Asthma Proc"},{"key":"563_CR18","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1186\/1750-1172-9-99","volume":"9","author":"E Aygoren-Pursun","year":"2014","unstructured":"Aygoren-Pursun E, Bygum A, Beusterien K, Hautamaki E, Sisic Z, Wait S, et al. Socioeconomic burden of hereditary angioedema: results from the hereditary angioedema burden of illness study in Europe. Orphanet J Rare Dis. 2014;9:99.","journal-title":"Orphanet J Rare Dis"},{"issue":"2","key":"563_CR19","doi-asserted-by":"publisher","first-page":"185","DOI":"10.2500\/aap.2014.35.3738","volume":"35","author":"P Nordenfelt","year":"2014","unstructured":"Nordenfelt P, Dawson S, Wahlgren CF, Lindfors A, Mallbris L, Bjorkander J. Quantifying the burden of disease and perceived health state in patients with hereditary angioedema in Sweden. Allergy Asthma Proc. 2014;35(2):185\u201390.","journal-title":"Allergy Asthma Proc"},{"key":"563_CR20","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1146\/annurev.iy.06.040188.003115","volume":"6","author":"AE Davis 3rd","year":"1988","unstructured":"Davis AE 3rd. C1 inhibitor and hereditary angioneurotic edema. Annu Rev Immunol. 1988;6:595\u2013628.","journal-title":"Annu Rev Immunol"},{"issue":"4","key":"563_CR21","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1016\/j.iac.2006.08.003","volume":"26","author":"AE Davis 3rd","year":"2006","unstructured":"Davis AE 3rd. Mechanism of angioedema in first complement component inhibitor deficiency. Immunol Allergy Clin North Am. 2006;26(4):633\u201351.","journal-title":"Immunol Allergy Clin North Am"},{"issue":"12","key":"563_CR22","doi-asserted-by":"publisher","first-page":"7994","DOI":"10.1074\/jbc.M709837200","volume":"283","author":"X Zhang","year":"2008","unstructured":"Zhang X, Tan F, Zhang Y, Skidgel RA. Carboxypeptidase M and kinin B1 receptors interact to facilitate efficient B1 signaling from B2 agonists. J Biol Chem. 2008;283(12):7994\u20138004.","journal-title":"J Biol Chem"},{"key":"563_CR23","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1186\/1742-2094-7-98","volume":"7","author":"AF Viana","year":"2010","unstructured":"Viana AF, Maciel IS, Dornelles FN, Figueiredo CP, Siqueira JM, Campos MM, et al. Kinin B1 receptors mediate depression-like behavior response in stressed mice treated with systemic E. coli lipopolysaccharide. J Neuroinflammation. 2010;7:98.","journal-title":"J Neuroinflammation"},{"issue":"2","key":"563_CR24","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/0306-4530(94)90009-4","volume":"19","author":"RM Bluthe","year":"1994","unstructured":"Bluthe RM, Pawlowski M, Suarez S, Parnet P, Pittman Q, Kelley KW, et al. Synergy between tumor necrosis factor alpha and interleukin-1 in the induction of sickness behavior in mice. Psychoneuroendocrinology. 1994;19(2):197\u2013207.","journal-title":"Psychoneuroendocrinology"},{"issue":"1","key":"563_CR25","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1038\/nrn2297","volume":"9","author":"R Dantzer","year":"2008","unstructured":"Dantzer R, O\u2019Connor JC, Freund GG, Johnson RW, Kelley KW. From inflammation to sickness and depression: when the immune system subjugates the brain. Nat Rev Neurosci. 2008;9(1):46\u201356.","journal-title":"Nat Rev Neurosci"},{"issue":"1","key":"563_CR26","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.neulet.2009.03.068","volume":"456","author":"JW Koo","year":"2009","unstructured":"Koo JW, Duman RS. Interleukin-1 receptor null mutant mice show decreased anxiety-like behavior and enhanced fear memory. Neurosci Lett. 2009;456(1):39\u201343.","journal-title":"Neurosci Lett"},{"issue":"6","key":"563_CR27","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1016\/j.jaci.2009.08.007","volume":"124","author":"F Bossi","year":"2009","unstructured":"Bossi F, Fischetti F, Regoli D, Durigutto P, Frossi B, Gobeil F Jr, et al. Novel pathogenic mechanism and therapeutic approaches to angioedema associated with C1 inhibitor deficiency. J Allergy Clin Immunol. 2009;124(6):1303-10 e4.","journal-title":"J Allergy Clin Immunol"},{"issue":"5","key":"563_CR28","doi-asserted-by":"publisher","first-page":"371","DOI":"10.2500\/aap.2014.35.3783","volume":"35","author":"WR Lumry","year":"2014","unstructured":"Lumry WR, Miller DP, Newcomer S, Fitts D, Dayno J. Quality of life in patients with hereditary angioedema receiving therapy for routine prevention of attacks. Allergy Asthma Proc. 2014;35(5):371\u20136.","journal-title":"Allergy Asthma Proc"},{"issue":"5","key":"563_CR29","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.1016\/j.jaip.2017.12.039","volume":"6","author":"WR Lumry","year":"2018","unstructured":"Lumry WR, Craig T, Zuraw B, Longhurst H, Baker J, Li HH, et al. Health-related quality of life with subcutaneous C1-inhibitor for prevention of attacks of hereditary angioedema. J Allergy Clin Immunol Pract. 2018;6(5):1733-41 e3.","journal-title":"J Allergy Clin Immunol Pract"}],"container-title":["Allergy, Asthma &amp; Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13223-021-00563-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13223-021-00563-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13223-021-00563-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,29]],"date-time":"2021-06-29T09:15:10Z","timestamp":1624958110000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacijournal.biomedcentral.com\/articles\/10.1186\/s13223-021-00563-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,29]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["563"],"URL":"https:\/\/doi.org\/10.1186\/s13223-021-00563-0","relation":{},"ISSN":["1710-1492"],"issn-type":[{"value":"1710-1492","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,29]]},"assertion":[{"value":"4 November 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 June 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the University of Calgary Ethics Board (REB# 17\u20130542) and all participants provided written informed consent prior to any study procedures.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"61"}}